COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light on the mechanisms of action, safety, and efficacy of CP using modern evidence-based medicine...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Franchini, Massimo, Pirofski, Liise-anne, Burnouf, Thierry, Paneth, Nigel, Joyner, Michael J., Casadevall, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491201/
https://www.ncbi.nlm.nih.gov/pubmed/35262370
http://dx.doi.org/10.1128/cmr.00200-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491201/
https://www.ncbi.nlm.nih.gov/pubmed/35262370
http://dx.doi.org/10.1128/cmr.00200-21

Ejemplares similares